Precision Oncology: 2024 in Review

Matteo Repetto1, Nicole Fernandez2, Alexander Drilon1,3

  • 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Cancer Discovery
|December 2, 2024
PubMed

Insights

Precision oncology in 2024 is advancing rapidly. Key developments include better patient selection using predictive molecular markers and improved combination therapies through rational drug design and repurposing.

Area of Science:

  • Oncology
  • Genomics
  • Pharmacology

Background:

  • Precision oncology aims to tailor cancer treatment to individual patients.
  • Identifying predictive molecular events is crucial for effective patient selection.
  • Advances in drug development are essential for improving therapeutic outcomes.

Purpose of the Study:

  • To summarize key advances in precision oncology during 2024.
  • To highlight evolving strategies in patient selection based on molecular markers.
  • To discuss progress in combination therapies, small-molecule inhibitor design, and drug repurposing.

Main Methods:

  • Review of recent literature and clinical trial data in precision oncology.
  • Analysis of emerging predictive molecular biomarkers.
  • Evaluation of novel therapeutic strategies including combination regimens and drug design.

Main Results:

  • Significant progress in identifying and utilizing predictive molecular events for patient stratification.
  • Advancements in developing strategic combination therapies.
  • Innovations in rational drug design for small-molecule inhibitors and structure-informed drug repurposing.

Conclusions:

  • Precision oncology continues to evolve with significant 2024 advancements.
  • Improved molecular profiling enhances patient selection for targeted therapies.
  • Novel drug development and repurposing strategies promise more effective cancer treatments.